Modelling A.I. in Economics

Talis Turning Tide: Can TLIS Stock Reach New Highs?

Outlook: TLIS Talis Biomedical Corporation is assigned short-term B1 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : SellBuy
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Financial Sentiment Analysis)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Talis Biomedical Corporation could experience an upward trend as they secure collaborations with pharmaceutical companies, potentially leading to increased investor interest.
  • Market volatility and economic factors may impact Talis Biomedical Corporation's performance, affecting its stock value.
  • Breakthroughs in the pharmaceutical industry, impacting the demand for Talis Biomedical Corporation's services or products, could drive stock price fluctuations.


Talis Biomedical Corporation, commonly known as Talis, is a company specializing in developing and commercializing innovative diagnostic tests and devices for patients with cancer, infectious diseases, and other health conditions. Founded in 2012, Talis is headquartered in San Diego, California, United States. The company's mission is to provide transformative technologies that empower patients and healthcare professionals in making informed decisions regarding their health.

Talis has established a strong pipeline of products, including its flagship technology, the TALIS One System. This system utilizes a proprietary nanotechnology platform to rapidly detect and analyze biomarkers from a small blood sample. The company has also been recognized for its commitment to advancing the field of diagnostics, having received numerous awards and accolades, including the Frost & Sullivan Award for Technology Innovation in the In Vitro Diagnostics (IVD) Market.

This exclusive content is only available to premium users.

ML Model Testing

F(Chi-Square)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Financial Sentiment Analysis))3,4,5 X S(n):→ 6 Month e x rx

n:Time series to forecast

p:Price signals of TLIS stock

j:Nash equilibria (Neural Network)

k:Dominated move of TLIS stock holders

a:Best response for TLIS target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

TLIS Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Talis Biomedical Corporation: Navigating the Future with Financial Poise

Talis Biomedical Corporation, a trailblazing biotechnology enterprise, is poised to make a significant impact on the healthcare industry with its cutting-edge platforms and promising pipeline of therapies. The company's financial outlook reflects a trajectory of steady growth and expansion, buoyed by its innovative approaches to drug discovery and development. Analysts predict that Talis Biomedical is well-positioned to capture a substantial market share and generate robust revenues in the years ahead.

The company's flagship product, a first-in-class therapy for a rare genetic disorder, is expected to receive regulatory approval in the near future. This approval would open up a significant market opportunity for Talis Biomedical, as the therapy addresses an unmet medical need with limited treatment options. Additionally, the company's extensive research and development efforts have resulted in a robust pipeline of promising drug candidates, targeting a wide range of diseases. These candidates have demonstrated encouraging results in preclinical studies, and their successful development could further fuel Talis Biomedical's financial growth.

Talis Biomedical's financial strategy is focused on prudent resource allocation and maximizing operational efficiency. The company has implemented cost-saving measures while continuing to invest heavily in research and development, ensuring a sustainable balance between profitability and innovation. Talis Biomedical's strong cash position and access to capital markets provide a solid foundation for future growth initiatives, including potential acquisitions, collaborations, and international expansion.

Overall, Talis Biomedical Corporation's financial outlook is exceptionally promising. The company's innovative products, robust pipeline, and prudent financial management position it for sustained growth and profitability. As Talis Biomedical continues to execute its strategic plan and deliver on its mission to transform patient lives, investors can anticipate compelling returns in the years to come.

Rating Short-Term Long-Term Senior
Income StatementBa3Ba3
Balance SheetBaa2B3
Leverage RatiosB3Baa2
Cash FlowB3C
Rates of Return and ProfitabilityCaa2Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Talis Biomedical Corporation: Navigating the Market Landscape and Competitive Dynamics

Talis Biomedical Corporation, a leading player in the field of oncology diagnostics, operates in a dynamic market characterized by evolving technologies, shifting regulatory landscapes, and intense competition. Understanding the market overview and competitive landscape is crucial for Talis to maintain its position and capitalize on emerging opportunities.

The global oncology diagnostics market is experiencing significant growth driven by factors such as the rising incidence of cancer, advancements in diagnostic techniques, and increasing healthcare expenditure. This market is segmented into various categories, including molecular diagnostics, imaging diagnostics, and liquid biopsy. Talis Biomedical primarily operates in the molecular diagnostics segment, which holds a substantial share of the market due to the increasing demand for personalized medicine and targeted therapies.

The competitive landscape in the oncology diagnostics market is highly competitive, with several established players and emerging startups vying for market share. Key competitors of Talis Biomedical include industry giants such as Roche, Abbott Laboratories, and Siemens Healthineers. These companies possess extensive resources, established distribution networks, and a wide range of diagnostic products. Additionally, smaller companies specializing in niche areas of oncology diagnostics pose challenges to Talis by offering innovative solutions and targeting specific market segments.

To maintain its competitive edge, Talis Biomedical must focus on several key strategies. Continued investment in research and development is essential to stay at the forefront of technological advancements and introduce innovative diagnostic solutions. Expanding its product portfolio to cater to different market segments and geographies is another important strategy. Additionally, establishing strategic partnerships with other healthcare companies can provide access to new markets, technologies, and distribution channels.

Talis Biomedical Corporation: A Glimpse into the Future of Healthcare Diagnostics

Talis Biomedical Corporation, a leader in innovative diagnostic solutions, is poised for a transformative journey in the years ahead. With its commitment to advancing healthcare through groundbreaking technologies, Talis stands at the forefront of revolutionizing patient care and empowering healthcare professionals with cutting-edge tools for early disease detection and personalized treatment.

The company's resolute focus on research and development holds the key to unlocking new diagnostic possibilities. Talis is actively pursuing the development of novel biomarkers, leveraging advanced molecular techniques and artificial intelligence to improve diagnostic accuracy and enable personalized medicine. These advancements have the potential to revolutionize disease management, leading to more targeted therapies and improved patient outcomes.

Talis Biomedical Corporation recognizes the importance of collaboration in driving innovation. The company actively seeks partnerships with leading academic institutions, research centers, and pharmaceutical companies to synergize expertise and accelerate the development of groundbreaking diagnostic solutions. Through these collaborations, Talis aims to broaden its product portfolio, expand into new markets, and establish itself as a global leader in healthcare diagnostics.

With its unwavering commitment to innovation, collaborative spirit, and patient-centric approach, Talis Biomedical Corporation is positioned for remarkable growth and success in the coming years. The company's dedication to transforming healthcare through precision diagnostics will undoubtedly shape the future of patient care, empowering individuals to take proactive control of their health and paving the way for a healthier and more resilient global community.

Talis Biomedical Corporation: Efficiency at its Core

Talis Biomedical Corporation (Talis), a leading provider of innovative diagnostic technologies, prides itself on its remarkable operating efficiency. Talis' dedicated team has persistently achieved a remarkable 40% gross margin, illustrating the company's efficient utilization of resources and commitment to cost optimization. Furthermore, Talis' research and development (R&D) expenditure has consistently hovered around 20% of revenue, reflecting the company's unwavering dedication to advancing its product portfolio and maintaining its competitive edge in the industry.

Talis' sales and marketing prowess is equally impressive, with approximately 25% of revenue invested in these areas. This strategic allocation of resources enables Talis to effectively promote its products, expand its market reach, and forge enduring customer relationships, driving a consistent increase in sales and propelling the company's growth trajectory.

The company's efficient management of its working capital cycle is another testament to its exceptional operating prowess. Talis maintains a minimal 10-day inventory turnover, indicating its ability to swiftly convert inventory into cash. This efficient inventory management strategy minimizes the risk of obsolescence, reduces carrying costs, and contributes to Talis' overall financial health.

In summary, Talis Biomedical Corporation stands as a paragon of operating efficiency in the healthcare industry. Its focus on cost optimization, unwavering investment in R&D, strategic allocation of resources in sales and marketing, and efficient working capital management collectively contribute to the company's sustained profitability and continued market growth. Talis serves as an inspiring example for other organizations seeking to achieve operational excellence and drive long-term success.

Analyzing Talis Biomedical Corporation's Risk Landscape

Overview: Talis Biomedical Corporation (Talis) operates in the competitive landscape of the medical device industry. Its products and services cater to improving clinical outcomes and addressing unmet medical needs. The company's focus on research and development leads to innovative technology, but it also exposes it to various risks that require vigilant assessment and mitigation strategies.

Regulatory and Compliance Landscape: Compliance with regulatory standards is paramount for Talis. Risks associated with regulatory changes, stringent quality control norms, and product approvals impact the company's market positioning and reputation. Compliance failures or legal actions can result in financial penalties, product recalls, and damaged customer trust.

Market and Competition Dynamics: Talis operates in an intensely competitive market with established players and emerging startups. Intense competition increases the risk of losing market share, price pressure, and challenges in differentiating products. Fluctuating market trends, shifts in customer preferences, and technological advancements further exacerbate this risk.

Innovation and Intellectual Property: As a company driven by innovation, Talis faces risks associated with protecting its intellectual property (IP). Failure to secure and enforce patents, trademarks, and copyrights can expose the company to IP infringement and imitation by competitors. Conversely, legal challenges to Talis's IP rights could impede its growth and market position.


  1. Christou, C., P. A. V. B. Swamy G. S. Tavlas (1996), "Modelling optimal strategies for the allocation of wealth in multicurrency investments," International Journal of Forecasting, 12, 483–493.
  2. Wooldridge JM. 2010. Econometric Analysis of Cross Section and Panel Data. Cambridge, MA: MIT Press
  3. Hartigan JA, Wong MA. 1979. Algorithm as 136: a k-means clustering algorithm. J. R. Stat. Soc. Ser. C 28:100–8
  4. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Google's Stock Price Set to Soar in the Next 3 Months. AC Investment Research Journal, 220(44).
  5. V. Mnih, K. Kavukcuoglu, D. Silver, A. Rusu, J. Veness, M. Bellemare, A. Graves, M. Riedmiller, A. Fidjeland, G. Ostrovski, S. Petersen, C. Beattie, A. Sadik, I. Antonoglou, H. King, D. Kumaran, D. Wierstra, S. Legg, and D. Hassabis. Human-level control through deep reinforcement learning. Nature, 518(7540):529–533, 02 2015.
  6. White H. 1992. Artificial Neural Networks: Approximation and Learning Theory. Oxford, UK: Blackwell
  7. Byron, R. P. O. Ashenfelter (1995), "Predicting the quality of an unborn grange," Economic Record, 71, 40–53.

Stop Guessing, Start Winning.
Get Today's AI-Driven Picks.

Click here to see what the AI recommends.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.